




A**B****C****FIG. 13A-13C**




Fig. 14




Fig. 15




Fig. 16





Fig. 17

TABLE 1: Characteristics of Recombinant WT1 Proteins Used for Serological Analysis

<u>Name</u>	<u>Recombinant Protein</u>	<u>WT1 Amino Acid Position</u>	<u>Molecular Weight</u>
WT1/full-length	Ra12-WT1 full length fusion protein	aa 1-449	85kDa
WT1/N-terminus	TRX-WT1 N-terminus fusion protein	aa 1-249	60kDa
WT1/C-terminus	WT1 C-terminus protein	aa 267-449	50kDa

Fig. 18

CID000622 Figure 1a Ab responses in group 0 and 1 (controls)




Control groups. A: 1:500 Dilution, B: 1:2000, C: 1: 8000, D: 1:16000

FIG. 19 A

25ug Ra12/WT1+MPL-SE, A: 1:500 Dilution, B: 1:2000, C: 1:8000, D: 1:16000


CID000622 Figure 1b. Ab responses in group 2 (25ug Ra12/WT1)



25ug Ra12/WT1+MPL-SE, A: 1:500 Dilution, B: 1:2000, C: 1:8000, D: 1:16000

FIG. 19B

CID000622 Figure 1c. Ab responses in group 3 (100ug Ra12/WT1)




WT1. Dose Titration. Ab responses to WT1. 100ug Ra12-WT1+MPL-SE. A: 1:500 Dilution, B: 1:2000, C: 1: 8000, D: 1:16000

FIG. 19C

CID000622 Figure 1d. Ab responses in groups 3 and 4 (1000ug Ra12/WT1)


Mouse Titration



WT1. Dose Titration. Ab responses to WT1. 1000ug Ra12-WT1+MPL-SE. A: 1:500 Dilution, B: 1:2000, C: 1:8000, D: 1:16000

FIG. 19D

Figure 1e. Ab responses in group 4 (1000ug Ra12/WT1)



WT1. Dose Titration. Ab responses to WT1. 1000ug Ra12-WT1+MPL-SE. A: 1:500 Dilution, B: 1:2000, C: 1: 8000, D: 1:16000

FIG. 19E

Figure 2a. Proliferative T-cell responses in WT1 protein immunized mice.
(Ra12WT1 dose titration, 3x in vivo, after 2IVS)




FIG. 20A

Figure 2b. Proliferative T-cell responses in WT1 protein immunized mice (Ra12WT1 dose titration, 6x in vivo, after 2IVS)





FIG. 20B


FIG. 21

**Figure 1. WT1 expression in human DC following
adeno WT1 and Vaccinia WT1 infection**


**Control
(uninfected
human DC**



**Adeno WT1
infected human
DC**



**Vaccinia WT1
infected human
DC**




46

FIG. 22

Figure 2. WT1 can be expressed reproducibly in human DC following adeno WT1 infection and is not induced by a control Adeno infection

**Control
(Adeno EGFP
infected
human DC)**



**Adeno WT1
infected human
DC**




FIG. 23

